Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP(®)) Biosimilar, to Those of NESP(®) After a Single Subcutaneous or Intravenous Administration to Healthy Subjects

INTRODUCTION: Darbepoetin alfa (NESP(®) and ARANESP(®)) has a sustained erythropoietic activity with a longer half-life than conventional recombinant human erythropoietin. CKD-11101 is under clinical development as a biosimilar of darbepoetin alfa. The purpose of this study was to compare the pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Inseung, Oh, Jaeseong, Kwon, Yu-Kyung, Yoon, Seo Hyun, Cho, Joo-Youn, Jang, In-Jin, Yu, Kyung-Sang, Lee, SeungHwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089108/
https://www.ncbi.nlm.nih.gov/pubmed/33953543
http://dx.doi.org/10.2147/DDDT.S303772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089108/
https://www.ncbi.nlm.nih.gov/pubmed/33953543
http://dx.doi.org/10.2147/DDDT.S303772

Ejemplares similares